Literature DB >> 15121157

MMPs, cadherins, and cell proliferation.

Sarah Jane George1, Amrita Dwivedi.   

Abstract

Proliferation of vascular smooth muscle cells plays a key role in the development of pathologic processes characterized by intimal thickening. Cadherins are adhesion receptors involved in homophilic cell-cell interactions, but they can also act as signaling molecules that affect cell behavior, including proliferation, migration. and survival. The matrix-degrading metalloproteinases (MMPs) are a family of proteolytic enzymes that modulate tissue remodeling, proliferation, and migration by degradation of extracellular matrix proteins as well as non-matrix proteins, including cadherins. This review discusses the key links between cadherins and MMPs in cell proliferation. A greater understanding of these processes may aid with the design of new clinical therapeutic approaches for atherosclerosis and restenosis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15121157     DOI: 10.1016/j.tcm.2003.12.008

Source DB:  PubMed          Journal:  Trends Cardiovasc Med        ISSN: 1050-1738            Impact factor:   6.677


  29 in total

1.  Herbal formula HMC05 prevents human aortic smooth muscle cell migration and proliferation by inhibiting the ERK1/2 MAPK signaling cascade.

Authors:  Yun Hwan Kang; In Jun Yang; Heung Mook Shin
Journal:  J Nat Med       Date:  2011-08-11       Impact factor: 2.343

2.  Mechanisms in photodynamic therapy: part two-cellular signaling, cell metabolism and modes of cell death.

Authors:  Ana P Castano; Tatiana N Demidova; Michael R Hamblin
Journal:  Photodiagnosis Photodyn Ther       Date:  2005-03       Impact factor: 3.631

3.  Targeted deletion of AP-2alpha leads to disruption in corneal epithelial cell integrity and defects in the corneal stroma.

Authors:  Dhruva J Dwivedi; Giuseppe F Pontoriero; Ruth Ashery-Padan; Shelley Sullivan; Trevor Williams; Judith A West-Mays
Journal:  Invest Ophthalmol Vis Sci       Date:  2005-10       Impact factor: 4.799

4.  A dynamic model of calcific nodule destabilization in response to monocyte- and oxidized lipid-induced matrix metalloproteinases.

Authors:  Rongsong Li; David Mittelstein; Juhyun Lee; Karen Fang; Rohit Majumdar; Yin Tintut; Linda L Demer; Tzung K Hsiai
Journal:  Am J Physiol Cell Physiol       Date:  2011-10-26       Impact factor: 4.249

5.  Gene expression signatures differ with extent of atherosclerosis in monkey iliac artery.

Authors:  Kathleen M Eyster; Susan E Appt; Connie J Mark-Kappeler; Abha Chalpe; Thomas C Register; Thomas B Clarkson
Journal:  Menopause       Date:  2011-10       Impact factor: 2.953

6.  Matrix metalloproteinase inhibitors suppress transforming growth factor-beta-induced subcapsular cataract formation.

Authors:  Dhruva J Dwivedi; Giuseppe Pino; Alice Banh; Zahra Nathu; Derek Howchin; Peter Margetts; Jacob G Sivak; Judith A West-Mays
Journal:  Am J Pathol       Date:  2006-01       Impact factor: 4.307

7.  Matrix metallopeptidase 2 activity in tendon regions: effects of mechanical loading exercise associated to anabolic-androgenic steroids.

Authors:  Rita C Marqueti; Jonato Prestes; Milena Paschoal; Oscar H P Ramos; Sérgio E A Perez; Hernandes F Carvalho; Heloisa S Selistre-de-Araujo
Journal:  Eur J Appl Physiol       Date:  2008-09-23       Impact factor: 3.078

8.  Antagonism of VEGF-A-induced increase in vascular permeability by an integrin α3β1-Shp-1-cAMP/PKA pathway.

Authors:  Soo Hyeon Kim; Young-Rak Cho; Hyeon-Ju Kim; Joa Sub Oh; Eun-Kyung Ahn; Hye-Jin Ko; Byung Joon Hwang; Seo-Jin Lee; Yongwan Cho; Yong Kee Kim; William G Stetler-Stevenson; Dong-Wan Seo
Journal:  Blood       Date:  2012-10-16       Impact factor: 22.113

Review 9.  Epac: effectors and biological functions.

Authors:  Sara S Roscioni; Carolina R S Elzinga; Martina Schmidt
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-01-05       Impact factor: 3.000

10.  Matrix Metalloproteinases as Mediators of Primary and Secondary Cataracts.

Authors:  Judith A West-Mays; Giuseppe Pino
Journal:  Expert Rev Ophthalmol       Date:  2007
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.